{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:04:50Z","timestamp":1775570690004,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"DOI":"10.7759\/cureus.102768","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T11:19:44Z","timestamp":1769944784000},"source":"Crossref","is-referenced-by-count":1,"title":["Maculopapular-Type Drug Eruption Caused by Cetuximab"],"prefix":"10.7759","author":[{"given":"Noriko","family":"Ikegawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuko","family":"Saito-Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S43628","article-title":"Cetuximab: its unique place in head and neck cancer treatment","volume":"7","author":"Specenier P","year":"2013","unstructured":"Specenier P, Vermorken JB. Cetuximab: its unique place in head and neck cancer treatment. Biologics. 2013, 7:77-90. 10.2147\/BTT.S43628","journal-title":"Biologics"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020412","article-title":"Cetuximab as a key partner in personalized targeted therapy for metastatic colorectal cancer","volume":"16","author":"Saoudi Gonz\u00e1lez N","year":"2024","unstructured":"Saoudi Gonz\u00e1lez N, Ros J, Baraibar I, et al.. Cetuximab as a key partner in personalized targeted therapy for metastatic colorectal cancer. Cancers (Basel). 2024, 16:412. 10.3390\/cancers16020412","journal-title":"Cancers (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose","volume":"358","author":"Chung CH","year":"2008","unstructured":"Chung CH, Mirakhur B, Chan E, et al.. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008, 358:1109-17. 10.1056\/NEJMoa074943","journal-title":"N Engl J Med"},{"key":"ref4","article-title":"Cutaneous adverse reactions specific to epidermal growth  factor receptor inhibitors","volume":"8","author":"Lupu I","year":"2015","unstructured":"Lupu I, Voiculescu V, Bacalbasa N, Prie B, Cojocaru I, Giurcaneanu C. Cutaneous adverse reactions specific to epidermal growth  factor receptor inhibitors. J Med Life. 2015, 8:57-61.","journal-title":"J Med Life"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14070","article-title":"Case of cetuximab-induced disseminated necrotic and maculopapular eruptions: involvement of an epidermal growth factor receptor inhibitor with epidermal necrosis","volume":"45","author":"Namiki T","year":"2018","unstructured":"Namiki T, Omigawa C, Nojima K, et al.. Case of cetuximab-induced disseminated necrotic and maculopapular eruptions: involvement of an epidermal growth factor receptor inhibitor with epidermal necrosis. J Dermatol. 2018, 45:e3-4. 10.1111\/1346-8138.14070","journal-title":"J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2013.10.001","article-title":"Tolerance and exhaustion: defining mechanisms of T cell dysfunction","volume":"35","author":"Schietinger A","year":"2014","unstructured":"Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 2014, 35:51-60. 10.1016\/j.it.2013.10.001","journal-title":"Trends Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nri3818","article-title":"The ins and outs of MHC class II-mediated antigen processing and presentation","volume":"15","author":"Roche PA","year":"2015","unstructured":"Roche PA, Furuta K. The ins and outs of MHC class II-mediated antigen processing and presentation. Nat Rev Immunol. 2015, 15:203-16. 10.1038\/nri3818","journal-title":"Nat Rev Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2009.07.001","article-title":"T cell epitope: friend or foe? Immunogenicity of biologics in context","volume":"61","author":"Weber CA","year":"2009","unstructured":"Weber CA, Mehta PJ, Ardito M, Moise L, Martin B, De Groot AS. T cell epitope: friend or foe? Immunogenicity of biologics in context. Adv Drug Deliv Rev. 2009, 61:965-76. 10.1016\/j.addr.2009.07.001","journal-title":"Adv Drug Deliv Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1126\/science.1108003","article-title":"Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate","volume":"307","author":"Delamarre L","year":"2005","unstructured":"Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science. 2005, 307:1630-4. 10.1126\/science.1108003","journal-title":"Science"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.10.046","article-title":"Alpha-gal IgE prevalence patterns in the United States: an investigation of 3,000 military recruits","volume":"12","author":"Ailsworth SM","year":"2024","unstructured":"Ailsworth SM, Susi A, Workman LJ, et al.. Alpha-gal IgE prevalence patterns in the United States: an investigation of 3,000 military recruits. J Allergy Clin Immunol Pract. 2024, 12:175-184.e5. 10.1016\/j.jaip.2023.10.046","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/jcia.2025.14348","article-title":"Establishment of \u03b1-gal-specific IgE cutoff value to prevent cetuximab-induced allergic reactions in potential \u03b1-gal syndrome","volume":"8","author":"Tian L","year":"2025","unstructured":"Tian L, Chinuki Y, Kohno K, et al.. Establishment of \u03b1-gal-specific IgE cutoff value to prevent cetuximab-induced allergic reactions in potential \u03b1-gal syndrome. J Cutan Immunol Allergy. 2025, 8:2025. 10.3389\/jcia.2025.14348","journal-title":"J Cutan Immunol Allergy"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2013.11.014","article-title":"Drug allergens and food--the cetuximab and galactose-\u03b1-1,3-galactose story","volume":"112","author":"Berg EA","year":"2014","unstructured":"Berg EA, Platts-Mills TA, Commins SP. Drug allergens and food--the cetuximab and galactose-\u03b1-1,3-galactose story. Ann Allergy Asthma Immunol. 2014, 112:97-101. 10.1016\/j.anai.2013.11.014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.11.030","article-title":"Mechanisms of allergen-specific immunotherapy","volume":"127","author":"Akdis CA","year":"2011","unstructured":"Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011, 127:18-27; quiz 28-9. 10.1016\/j.jaci.2010.11.030","journal-title":"J Allergy Clin Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/458145-maculopapular-type-drug-eruption-caused-by-cetuximab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T11:19:45Z","timestamp":1769944785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/458145-maculopapular-type-drug-eruption-caused-by-cetuximab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.102768","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}